Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery is now commercially available in the U.S., according to a press release from Eyenovia.

A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic acid 6% in petrolatum that should be applied in the evening to his elbows and knees ...

26, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic ...

This agreement will effectively expand the existing collaboration agreement between the companies, which was signed in February 2023, which included the testing of clobetasol propionate in the ...

Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Apotex for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic ...

The notification introduces SION No. A-3682, which pertains to the export product clobetasol propionate, a key pharmaceutical compound, under the Chemical and Allied Product group (Product Code 'A').

Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid ...

APP13007's active ingredient is the corticosteroid clobetasol propionate, and it is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. This novel formulation ...

This agreement will effectively expand Eyenovia and Formosa's existing collaboration agreement signed in February 2023 which included the testing of clobetasol propionate in the Optejet ® and a ...